News

‘Clinically diagnosed cases’ included in Hubei to effectively fix a loophole in COVID-19 spread – Global Times

The highly read Chinese news outlet, Global Times, offers additional insights into the new procedures for coronavirus diagnosis in Hubei province, which led to a big jump in the new confirmed cases in the epicenter and sent the financial markets across Asia into a tailspin.

Key Quotes:

"A suspected case will be clinically diagnosed as long as the patient shows pulmonary lesions typical of the new coronary pneumonia following a CT scan, even if they have not been given a nucleic acid test.

There are patients whose nucleic acid tests do not appear positive in the lab, but they cannot be ruled out as a potential infection.

In such cases, individuals could easily transmit the virus to the public. Including such patients in reports of new cases will facilitate quarantine measures and allow them to receive medical treatment in hospitals, which is good for both the patients and the public at the same time."

Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.


RELATED CONTENT

Loading ...



Copyright © 2024 FOREXSTREET S.L., All rights reserved.